Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Verona
Pharma
Merck pays $10B to acquire Verona and COPD drug Ohtuvayre
Merck has agreed to a $10-billion buyout of Verona Pharma and its first-in-class, potential COPD blockbuster Ohtuvayre.
Kevin Dunleavy
Jul 9, 2025 11:25am
Verona's new COPD drug Ohtuvayre racked up sales of $42M in 2024
Jan 7, 2025 1:27pm
FDA signs off on Regeneron and Sanofi's Dupixent for COPD
Sep 27, 2024 9:40am
Verona's price for COPD drug far exceeds ICER's valuation
Jul 16, 2024 2:31pm
EU signs off on Regeneron and Sanofi's Dupixent for COPD
Jul 3, 2024 10:05am
Verona earns FDA nod for potential blockbuster to treat COPD
Jun 26, 2024 6:26pm
